Bearing in mind that “we vaccinated the population over 55 years of age in Chile, we believe that we could authorize it,” said García, during a news conference.
The Ad5-nCoV vaccine thus joins the three that have already received authorization in Chile: the one produced by the German-American conglomerate Pfizer / BioNTech, that of the Chinese laboratory Sinovac and the British one of AstraZeneca.
Unlike other vaccines, this requires refrigeration between 2 and 8 degrees Celsius for up to three months, which facilitates the distribution process.
The vaccine, which is a viral vector and whose methodology is based on that used against Ebola, has already been authorized in China, Pakistan, Hungary and Mexico.
According to the first results, it is 65.7% effective in symptomatic cases and 90.9% in severe cases, the authorities explained.
Chile, which has already committed more than 35 million doses, is one of the countries with the highest percentage of the vaccinated population and, since February, more than 7.1 million people have received at least one dose (about 4.2 million both injections).
The country, with more than 1 million infected and 23,796 deaths in one year, is experiencing, however, the worst moments of the pandemic, with hospitals on the verge of collapse and more than 83% of the population in strict confinement.
The virulence of the pandemic, in which the Brazilian and British variants play a key role, led the Chilean government to announce the closure of the borders for a month, which took effect last Monday.
The Chilean government believes that the first effects of the vaccination will be noticed in mid-April and is confident that for the eventual elections in May, there will be 9.3 million people with at least one dose.
Get the latest news delivered to your inbox
Follow us on social media networks